Welcome to LookChem.com Sign In|Join Free

CAS

  • or

260806-90-4

Post Buying Request

260806-90-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

260806-90-4 Usage

General Description

Methyl 3-bromo-2-methoxybenzoate is a chemical compound with the molecular formula C9H9BrO3. It is an ester, which means it is derived from a reaction between an acid and an alcohol. This particular compound is formed from the reaction of 3-bromo-2-methoxybenzoic acid with methanol. Methyl 3-bromo-2-methoxybenzoate is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also used as a reagent in organic synthesis to introduce the 3-bromo-2-methoxybenzoyl functional group into different molecules. methyl 3-bromo-2-methoxybenzoate is important in research and development of new products in the pharmaceutical and agricultural industries.

Check Digit Verification of cas no

The CAS Registry Mumber 260806-90-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,6,0,8,0 and 6 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 260806-90:
(8*2)+(7*6)+(6*0)+(5*8)+(4*0)+(3*6)+(2*9)+(1*0)=134
134 % 10 = 4
So 260806-90-4 is a valid CAS Registry Number.
InChI:InChI=1/C9H9BrO3/c1-12-8-6(9(11)13-2)4-3-5-7(8)10/h3-5H,1-2H3

260806-90-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name methyl 3-bromo-2-methoxybenzoate

1.2 Other means of identification

Product number -
Other names 3-bromo-2-methoxy-benzoic acid methyl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:260806-90-4 SDS

260806-90-4Relevant articles and documents

MODIFIED PROTEINS AND PROTEIN DEGRADERS

-

Paragraph 00639-00641, (2021/12/08)

Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.

Extended structure-activity study of thienopyrimidine-based EGFR inhibitors with evaluation of drug-like properties

Bugge, Steffen,Buene, Audun Formo,Jurisch-Yaksi, Nathalie,Moen, Ingri Ullestad,Skj?nsfjell, Ellen Martine,Sundby, Eirik,Hoff, B?rd Helge

, p. 255 - 274 (2015/11/27)

Thieno[2,3-d]pyrimidines are attractive derivatives for cancer treatment, among others through regulation of the epidermal growth factor receptor tyrosine kinase (EGFR-TK). In an extended SAR study, 44 new compounds of this class have been evaluated as inhibitors, while simultaneously focussing on ADME properties. Through the application of bioisosters, hybrid structures, solubilizing tails, and a combination approach several successful alterations in terms of activity and physiochemical properties were accomplished. Compounds based on benzylamines were found superior to aniline hybrid structures with respect to activity and ADME profile. Exploration of the former class revealed meta-and para amides as favourable 6-aryl substituents, contributing to an increase in activity and acting as a linker for solubilizing tails. Next, combinations of activity-inducing groups on the same scaffold resulted in new drug candidates. Compounds containing 6-aryls with the (2-(dimethylamino)ethyl)carbamoyl substituent were found equipotent to Erlotinib. Compared to this commercial drug, improved solubility and metabolic stability were observed. However, the thieno[2,3-d]pyrimidines with a solubilizing tail was by Caco-2 experiments found to have permeability issues, making further drug development difficult. Selected compounds were further analysed for toxicity and teratogenicity in zebrafish embryos. Two thienopyrimidines were both found to be less lethal than Erlotinib and to perform as well in terms of teratogenicity. Finally, the most promising thienopyrimidine drug was evaluated in a panel of human cancer cell lines, showing a clear potential for thienopyrimidines as anti-cancer agents.

HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS

-

Page/Page column 198, (2010/01/07)

The present invention provides compound of Formula (I): or a stereoisomer, tautomer, salt or solvate thereof, wherein the variables are defined herein. The compounds of formula (I) are inhibitors of Bcl-2 family antiapoptotic proteins, compositions containing the compounds and methods of treating diseases using the compounds.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 260806-90-4